@bbrunoneves@MakisMedicine Olá Bruno, procure no Pubmed os trabalhos sobre estas moléculas reposicionadas. No Substack do Makis (que vc diz acompanhar há 2 anos) há referências, e a partir delas você acha muita coisa.
🚨 SCIENTISTS ARE NOW STUDYING WHY IVERMECTIN MAY TARGET THE “ROOT” OF CANCER THAT CHEMO OFTEN LEAVES BEHIND
This is the part almost nobody talks about.
Researchers have spent years studying how certain repurposed antiparasitic drugs interact with cancer cells at the molecular level.
And one area getting major attention?
Cancer stem cells.
These are the cells many researchers believe may help tumors:
✅ Return years later
✅ Spread through the body
✅ Develop resistance to chemotherapy
✅ Survive even after aggressive treatment
What makes Ivermectin so controversial in cancer research is that laboratory studies suggest it may interact with these resistant stem like cancer cells differently than traditional chemo. (PMC)
Researchers are ALSO studying:
✅ How Ivermectin may help reverse chemotherapy resistance
✅ How Fenbendazole & Mebendazole may disrupt glucose uptake in tumor cells
✅ How repurposed drugs may affect pathways tied to tumor growth and survival (MDPI)
This is why the conversation around repurposed drugs has absolutely exploded online.
Not because people are “crazy.”
Because people are seeing:
• 400+ published papers
• Ongoing cancer research
• Growing scientific interest
• More doctors openly discussing mechanisms
⚠️ Not a medical advice. Consult your doctor before taking any medications.
Explore these meds on: @PharmacyinUSA
#Ivermectin #CancerCure
local AI does not imply, “uncensored is better,” but since commercial AI is an unaccountable gatekeeper over legitimate scientific inquiry in politically sensitive domains, local AI needs to provide honest, sovereign, local, reproducible, safety-bounded scientific assistance.
BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal
84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.
Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.
At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:
No evidence of disease (32.8%)
Tumor regression (15.6%)
or Cancer stabilization (36.1%)
Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.
Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.
This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.
With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.
In the meantime, many cancer patients are exercising their right to try.
@twc_health@McCulloughFund@IIAR_Journals@P_McCulloughMD@DrHarveyRisch@DrKellyVictory@jathorpmfm@drdrew@PeterGillooly@FosterCoulson
A stunning revelation from the front lines of medicine. Dr. William Makis is reporting unprecedented success using ivermectin for two of our most devastating neurological conditions: Parkinson's and Alzheimer's disease.
His accidental discovery is yielding results that defy conventional expectations. For Parkinson's, high-dose ivermectin (60-72mg) is facilitating remarkable recoveries. Patients on maximum standard treatments, once barely mobile, are now experiencing dramatic improvements in movement and symptoms. One such patient, after a few weeks of treatment, returned to playing golf—an activity lost for years.
The outcomes in Alzheimer's are even more profound. Dr. Makis details how family members, following his protocol of low-dose ivermectin (12-24mg for a few days), are witnessing what can only be described as medical miracles.
Loved ones who had not recognized family members for years are suddenly reconnecting. Memories are flooding back; cognitive abilities are being restored. In one extraordinary case, a patient was taken off hospice after their condition improved so drastically.
The stories are heart-rending: "My grandma's back." Families are reclaiming precious time with loved ones they felt they had lost forever. All from a few pills of a medication with a well-established safety profile.
Dr. Makis challenges the medical establishment, noting that supportive preclinical research on ivermectin and Alzheimer's appears to have been scrubbed from mainstream search engines, a silent testament to the battle over this repurposed drug.
He urges the public to look at the evidence he shares on his platforms. The potential for a safe, accessible, and effective treatment for these neurodegenerative scourges is too significant to ignore.
The question remains: When the evidence is this compelling, and the reward is the reversal of human suffering, why isn't this being researched at the highest levels?
🚨🚨 Dosificación de ivermectina y fenbendazol según protocolo contra el cáncer del Dr William Makis...
Estos medicamentos reutilizados se diseñaron originalmente para combatir parásitos, pero la investigación y el uso en la práctica han demostrado que prometen mucho más...Cada uno ataca el cáncer en múltiples frentes biológicos, ayudando a detener el crecimiento tumoral, inactivando las células cancerosas, fortaleciendo el sistema inmunitario y mucho más...
💊 IVERMECTINA – 12 Acciones Anticáncer Conocidas:
1. Inhibe la vía WNT/β-catenina: detiene la proliferación de células cancerosas.
2. Induce la apoptosis: desencadena la muerte programada de las células cancerosas.
3. Bloquea las proteínas transportadoras de importina α/β, lo que impide la replicación de células cancerosas.
4. Inhibe la enzima PAK1: reduce la inflamación y la progresión tumoral.
5. Antiangiogénico: detiene la formación de nuevos vasos sanguíneos en los tumores.
6. Modulador del sistema inmunológico: mejora el reconocimiento de las células cancerosas.
7. Disruptor de la autofagia: interfiere con las estrategias de supervivencia de las células cancerosas.
8. Se dirige a las células madre del glioblastoma: eficaz en cánceres cerebrales.
9. Inhibe la respiración mitocondrial: corta el suministro de energía a los tumores.
10. Interrumpe la señalización de mTOR, lo que ralentiza el crecimiento celular.
11. Supera la resistencia a la quimioterapia: hace que la quimioterapia sea más efectiva.
12. Propiedades antivirales: potencialmente útiles para cánceres relacionados con virus (como el VPH).
💊 FENBENDAZOL – 12 Acciones Anticancerígenas Conocidas:
1. Alteración de los microtúbulos: impide que las células cancerosas se dividan.
2. Inhibe la absorción de glucosa: priva a las células cancerosas de energía.
3. Activa el gen supresor de tumores p53, que ayuda a eliminar las células dañadas.
4. Desencadena la apoptosis (muerte celular), especialmente en el cáncer de pulmón, colon y próstata.
5. Inhibe la metástasis: evita que el cáncer se propague.
6. Aumenta el estrés oxidativo en las células cancerosas, haciéndolas más vulnerables.
7. Modulador inmunitario: puede ayudar al sistema inmunitario a atacar los tumores.
8. Bloquea la angiogénesis: impide que los tumores generen suministro de sangre.
9. Agota el glutatión en los tumores, lo que debilita sus defensas.
10. Suprime la vía de señalización de AKT, implicada en la supervivencia celular.
11. Restaura la regulación normal del ciclo celular: previene el crecimiento descontrolado.
12. Sinérgico con otros agentes naturales (p. ej., CBD, curcumina, vitamina D).
🚨🚨 Desparasítate con clavo de olor...
¿Los parásitos ocultos te quitan energía?
¿Te sientes hinchado, fatigado o con brotes? Los parásitos podrían ser la causa oculta de estos síntomas, son mucho más comunes de lo que crees...
Roban tus nutrientes, alteran la salud intestinal y debilitan el sistema inmunitario.. Si no se controlan, pueden causar:
- Hinchazón crónica y problemas digestivos
- Fatiga inexplicable
- Afecciones cutáneas como eczema o acné
📌📌 Agua de clavo: una limpieza natural contra parásitos:
El clavo contiene eugenol, un potente compuesto que interrumpe el ciclo de vida de los parásitos. A diferencia de los tratamientos sintéticos, el agua de clavo no solo elimina los parásitos adultos, sino que también ataca a los huevos, previniendo la reinfestación...
Se ha demostrado que el eugenol:
- Descompone las membranas de los parásitos, inactivándolas
- Elimina los huevos, previniendo futuras infestaciones
- Mejora la digestión, creando un ambiente hostil para los parásitos.
Modo de empleo:
Hierva 1 taza de agua y añada 1 cucharadita de clavos de olor enteros.
Deje reposar de 10 a 15 minutos
Cuélelo y tómelo tibio en ayunas
Repita su uso diariamente durante 7 a 14 días para obtener mejores resultados...
🔥Dr. Berg explains how cancer behaves like a parasite.
The shocking part?
Cheap antiparasitic meds like Fenbendazole and Ivermectin target those exact mechanisms.
Why no big clinical trials from major centers? Expired patents = no pharma profits.
Ivermectin and Mebendazole Hit Cancer Cells Six Different Ways. Chemo Usually Hits One.
That's why combination chemotherapy exists — because cancer has to be attacked through multiple mechanisms simultaneously. Ivermectin and mebendazole together do exactly that: blocking cell division, cutting off glucose metabolism, targeting cancer stem cells, and more. Six distinct anti-cancer mechanisms in one affordable, already-approved combination.
Join the Fight: https://t.co/rvCeXmwbdp
Courtesy of The Lance Wallnau Show @lancewallnau
#MedicalFreedom
We found 84% of cancer patients taking ivermectin and mebendazole for 6 months declared their cancer was either COMPLETELY GONE, REGRESSED, or STOPPED SPREADING.
It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.
Imagens do verdadeiro golpe. CPX Infiltrados pelos narcovassalos saindo da "invasão antidemocrática do Senado", sendo atacados pelos que, em seguida, foram presos por crimes contra a democracia. Que vergonha!!!!
https://t.co/Uru6tftXeP
Congratulations @elonmusk! This is an amazing milestone. Time to move on the a Neural Link-controlled exoskeletomaton that will interact with the user's muscle activation AI assisted by neural control in high granularity. This man may hike with his kids and even play golf!
Last night I spoke with Brad Smith @ALScyborg, the first person with ALS to have @neuralink implanted. He has his voice back through AI and can even make dad jokes again. Absolutely incredible technology changing lives and bettering humanity. Thank you @elonmusk!
Cirurgiã oncológica afirma que a ivermectina é mais segura que uma simples pílula de açúcar e ainda diz ter visto casos de câncer em estágio 4 recuarem.
Cirurgiã oncológica afirma que a ivermectina é mais segura que uma simples pílula de açúcar e ainda diz ter visto casos de câncer em estágio 4 recuarem.
@JeterAlatz21760 Olá Jeter, revisões bibliográficas indicam que, há vários anos, estas moléculas contra o câncer têm mostrado grande potencial , bem antes de terem sido combatidas ferozmente para a emissão de Autorização de Uso Emergencial (EUA) para a venda em massa de SARS-CoV-2 vaxx.
Maior Estudo em Mundo Real de Ivermectina + Mebendazol em Pacientes com Câncer Mostra 84,4% de Benefício Clínico — Quase METADE Relata Desaparecimento do Câncer ou Regressão de Tumor
Após apenas 6 meses, 48,4% dos pacientes com câncer que tomavam ivermectina e mebendazol relataram NENHUMA EVIDÊNCIA DE DOENÇA (32,8%) ou regressão de tumor (15,6%), enquanto 36,1% relataram estabilização da doença��️
Completamos a maior análise em humanos em mundo real até o momento, avaliando ivermectina e mebendazol em pacientes com câncer — e os resultados representam um dos sinais clínicos mais convincentes já documentados para terapias anti-parasitárias repropositadas em oncologia.
A análise inovadora foi possível graças a uma colaboração única entre The Wellness Company, the McCullough Foundation, e o Chairman do President’s Cancer Panel (Dr. Harvey Risch) — unindo dados clínicos em mundo real, experiência médica de linha de frente e expertise epidemiológica de alto nível para entregar insights urgentemente necessários em oncologia.
Trata-se de uma avaliação prospectiva de programa clínico em mundo real de 197 pacientes com câncer, com 122 completando uma pesquisa de acompanhamento em cerca de seis meses (taxa de resposta: 61,9%).
Pacientes com câncer foram prescritos ivermectina–mebendazol composta, com cada cápsula contendo 25 mg de ivermectina e 250 mg de mebendazol — mais comumente tomada em 1–2 cápsulas por dia.
A coorte representou uma população clinicamente relevante, incluindo uma ampla variedade de tipos de câncer, com 37,1% dos pacientes relatando doença ativamente progressiva no baseline e muitos já tendo passado por quimioterapia, radioterapia e cirurgia.
Aos seis meses, 84,4% dos pacientes com câncer relataram benefício clínico (Razão de Benefício Clínico: 84,4% [IC 95%: 77,0–89,8%]):
✅ 32,8% relataram nenhuma evidência de doença (IC 95%: 25,1–41,5%)
✅ 15,6% relataram regressão de tumor (IC 95%: 10,2–23,0%)
✅ 36,1% relataram doença estável (IC 95%: 28,1–44,9%)
A adesão ao tratamento foi alta, com 86,9% completando o protocolo completo e 66,4% permanecendo em terapia aos seis meses.
O regime foi bem tolerado, com 25,4% relatando efeitos colaterais, principalmente leves e gastrointestinais, e mais de 93% continuando o tratamento apesar desses eventos.
Os pacientes foram tratados em condições de mundo real ao lado de terapias concomitantes, incluindo quimioterapia (27,9%), radioterapia (21,3%), cirurgia (19,7%), suplementos (49,2%) e modificação dietética (37,7%), apoiando o uso como abordagem adjuvante.
Juntas, essas descobertas representam um grande sinal clínico em mundo real, internamente consistente, que apoia a URGENTE investigação adicional de ivermectina e mebendazol como terapias adjuvantes de câncer de baixa toxicidade.
Dada a força do sinal observado aqui, avançar nessa linha de investigação não é mais opcional — é necessário.
Isso NÃO é o fim. Continuaremos avançando esse trabalho com conjuntos de dados maiores para definir e validar ainda mais o papel dos anti-parasitários nos resultados do câncer.
O manuscrito está agora disponível como preprint no repositório de pesquisa Zenodo, operado pela European Organization for Nuclear Research, enquanto passa por revisão por pares em jornais líderes de oncologia: “Resultados Clínicos em Mundo Real de Ivermectina e Mebendazol em Pacientes com Câncer: Resultados de uma Coorte Observacional Prospectiva.”
@twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson
@miltonmanhaes Olá @miltonmanhaes, revisões bibliográficas indicam que, há vários anos, estas moléculas contra o câncer têm mostrado grande potencial , bem antes de terem sido combatidas ferozmente para a emissão de Autorização de Uso Emergencial (EUA) para a venda em massa de SARS-CoV-2 vaxx.
Less than 0.33% of what I post on X is seen. AI says this is not shadow-banning, just that I am posting "uninteresting content". Nothing to do with me openly being critical and canceling the Grok paid plan due to bullying and harassment from this service. George Orwell explains.